Merck’s Keytruda application in adenocarcinoma accepted by FDA
The Fly

Merck’s Keytruda application in adenocarcinoma accepted by FDA

Merck announced the FDA has accepted for review a new supplemental Biologics License Application seeking approval for Keytruda, Merck’s anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. The sBLA is based on data from the KEYNOTE-859 trial, in which Keytruda plus chemotherapy demonstrated a statistically significant improvement in overall survival versus chemotherapy alone, regardless of PD-L1 expression, in patients who were human epidermal growth factor receptor 2 negative. The FDA has set a Prescription Drug User Fee Act target action, date of December 16, 2023. Keytruda is currently approved in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma in the U.S. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on MRK:

Related Articles
Vince CondarcuriHealthcare Stocks Rise despite Medicare Price Cuts for Their Drugs
TheFlyBiden administration announces lower prices for 10 Medicare drugs in 2026
TheFlyU.S. to announce prices for drugs in Medicare negotiations, NY Times says
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App